OTLK · Outlook Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $1.51M | - | - | - | - | - | - | - |
| Cost of Revenue | $149.3K | $29.6K | $439.8K | - | - | - | - | - | - | - |
| Gross Profit | ($21.9K) | ($1.24M) | $1.07M | - | - | - | - | - | - | - |
| R&D | $4.50M | $3.63M | $7.13M | $4.41M | $9.66M | $11.20M | $13.51M | $4.53M | $11.10M | $544.9K |
| SG&A | $7.98M | $11.95M | $9.68M | $7.98M | $11.95M | $8.36M | $5.43M | $5.79M | $7.04M | $6.29M |
| Total Operating Expenses | - | - | - | - | - | $18.14M | $18.94M | - | - | - |
| D&A | - | $30.1K | - | - | $28.8K | - | - | $28.2K | - | - |
| Operating Income | ($14.03M) | ($13.48M) | ($15.75M) | ($12.39M) | ($21.61M) | ($19.56M) | ($18.94M) | ($10.32M) | ($18.14M) | ($6.84M) |
| Interest Expense | - | - | - | - | - | $303 | - | - | - | - |
| Income Tax | - | - | - | $2.8K | - | - | $2.8K | - | - | $2.8K |
| Net Income | ($4.45M) | ($23.06M) | ($20.15M) | ($46.36M) | $17.38M | $44.41M | ($114.29M) | ($11.18M) | ($20.68M) | ($6.65M) |
| EPS - Basic | ($0.05) | ($0.38) | ($0.55) | ($1.50) | $0.72 | $1.91 | ($8.01) | ($0.80) | ($1.60) | ($0.60) |
| EPS - Diluted | ($0.05) | ($0.38) | ($0.55) | ($1.50) | $0.72 | ($0.89) | ($8.01) | ($0.80) | ($1.60) | ($0.60) |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.75M | $8.68M | $8.08M | $7.56M | $5.70M | $14.93M | $47.23M | $10.36M | $23.39M | $43.63M |
| Accounts Receivable | $2.72M | $114.6K | $1.49M | - | - | - | - | - | - | - |
| Inventory | $3.34M | $3.46M | $3.34M | $3.60M | $3.11M | - | - | - | - | - |
| Accounts Payable | $13.64M | $7.32M | $10.19M | $7.77M | $12.19M | $7.97M | $4.36M | $3.48M | $6.57M | $3.62M |
| Current Assets | $20.90M | $17.17M | $17.39M | $17.81M | $15.67M | $27.42M | $57.79M | $20.39M | $30.98M | $53.05M |
| Total Assets | $21.89M | $18.24M | $18.58M | $19.08M | $17.01M | $28.82M | $59.03M | $21.68M | $32.30M | $54.02M |
| Current Liabilities | $38.88M | $49.06M | $45.81M | $24.82M | $48.24M | $42.55M | $54.08M | $45.97M | $46.73M | $43.53M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $50.89M | $56.79M | $50.77M | $51.54M | $67.30M | $101.90M | $193.26M | $46.03M | $46.74M | $43.54M |
| Stockholders' Equity | ($28.99M) | ($38.55M) | ($32.19M) | ($32.46M) | ($50.29M) | ($73.08M) | ($134.24M) | ($24.34M) | ($14.44M) | $10.49M |
| Retained Earnings | ($633.22M) | ($628.77M) | ($605.71M) | ($572.26M) | ($525.91M) | ($543.28M) | ($593.39M) | ($479.10M) | ($467.92M) | ($434.25M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($14.94M) | - | - | ($10.97M) | - | - | ($13.03M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | $15.53M | - | - | $1.74M | - | - | ($3.2K) | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | 70.8% | - | - | - | - | - | - | - |
| Operating margin | - | - | -1046.2% | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | -1338.8% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | 474.0% | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 643.0% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -20.3% | -126.4% | -108.4% | -243.0% | 102.2% | 154.1% | -193.6% | -51.5% | -64.0% | -12.3% |
| Return on equity | 15.4% | 59.8% | 62.6% | 142.8% | -34.6% | -60.8% | 85.1% | 45.9% | 143.2% | -63.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.54 | 0.35 | 0.38 | 0.72 | 0.32 | 0.64 | 1.07 | 0.44 | 0.66 | 1.22 |
| Quick ratio | 0.45 | 0.28 | 0.31 | 0.57 | 0.26 | 0.64 | 1.07 | 0.44 | 0.66 | 1.22 |
| Cash ratio | 0.20 | 0.18 | 0.18 | 0.30 | 0.12 | 0.35 | 0.87 | 0.23 | 0.50 | 1.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -64563.3x | - | - | - | - |
| Equity multiplier | -0.76 | -0.47 | -0.58 | -0.59 | -0.34 | -0.39 | -0.44 | -0.89 | -2.24 | 5.15 |
| Liabilities / Assets | 2.32 | 3.11 | 2.73 | 2.70 | 3.96 | 3.54 | 3.27 | 2.12 | 1.45 | 0.81 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.08 | - | - | - | - | - | - | - |
| Inventory turnover | 0.04 | 0.01 | 0.13 | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | 362d | - | - | - | - | - | - | - |
| Days inventory outstanding | 8174d | 42604d | 2771d | - | - | - | - | - | - | - |
| Days payable outstanding | 33330d | 90168d | 8459d | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | -5327d | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | 2.6x | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | 533.5x |
| P / S | - | - | 26.0x | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -13.2% | 37.6% | 19.5% | 34.6% | -109.3% | -7.8% | -177.0% | 34.2% | -6.6% | 63.8% |
| Net income growth (YoY) | 90.4% | - | - | 59.4% | - | - | -1617.5% | 40.1% | -17.9% | 66.2% |
| EPS growth (YoY) | 96.7% | - | 38.2% | 81.3% | - | 44.4% | -1235.0% | -900.0% | -1900.0% | -566.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 10.7% | 23.3% | 56.0% | 75.8% | -106.6% | -406.1% | - | - | - | -70.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$1.41M totalDevelopment And Commercialization Of Ons5010 Or Lytenava$1.41M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Outlook Therapeutics against the 5 most active filers in the same SIC group.